Cambridge Biolink

Innovative Approaches to Biomarker Discovery and Validation

Thursday, October 1, 2009 @ 4:00 PM
Microsoft New England Research and Development Center (Kendall Square)

View RSVP List

As personalized medicine continues to evolve, the impact of biomarkers and technologies to discover them take on an increased level of importance in accelerating clinical and translational research and in development of medicines and treatments for a wide range of diseases.

Join world-class scientists and technology executives for thought- provoking conversation and presentations on cutting-edge work in: biomarker discovery in oncology therapeutics at Merck Research Laboratories and the Metabolite Profiling Initiative at the Broad Institute; and the co-founders of Gene Network Sciences and Linguamatics representing technologies that enhance drug efficacy and safety through a more sophisticated understanding of drug effects on the human body.

Please join us for an informal wine and cheese reception with the speakers and colleagues in the industry.

Sponsors

Confirmed Speakers:

Clary Clish: PhD, Director of the Metabolite Profiling Initiative, Broad Institute

Colin Hill: CEO and Co-founder, Gene Network Sciences

David Milward: PhD, CTO and Co-founder, Linguamatics, Cambridge, UK

James Watters: PhD, Associate Director, Merck Research Laboratories

PA Moderator: O. Prem Das, PhD, CEO, Synostics

Program Organizers:

Jason Johnson, PhD, Executive Director, Merck Research Laboratories and Pearl Freier, President, Cambridge BioPartners